NCT05683418 2026-04-22
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Totus Medicines
Phase 1 Recruiting
Totus Medicines
Bristol-Myers Squibb
Stanford University
M.D. Anderson Cancer Center
Incyte Corporation
National Cancer Institute (NCI)
Royal Marsden NHS Foundation Trust
West China Hospital